Market Cap 275.38B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 15.06
Forward PE 14.73
Profit Margin 23.09%
Debt to Equity Ratio 0.73
Volume 1,700,678
Avg Vol 1,309,688
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 51%
Beta 0.64
Analysts Sell
Price Target $122.43

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01
Address:
Lichtstrasse 35, Basel, Switzerland
keypatience
keypatience Oct. 27 at 5:16 PM
$XBI $NVS Novartis on a buying spree
0 · Reply
Stone52
Stone52 Oct. 27 at 4:20 PM
$AQST $SPRY $NVS $RNA M&A in the biotech space continues to heat up as Novartis is buying U.S. biotech firm Avidity Biosciences for about $12 billion in cash - announced this morning. Neither AQST or SPRY will be stand-alone companies at some point.
1 · Reply
Jaythelest
Jaythelest Oct. 27 at 4:10 PM
$NVS $DYN So logically $ONCY are the next to be acquire , they need us 💪
0 · Reply
DarkWave_12
DarkWave_12 Oct. 27 at 3:57 PM
$NVS I’m leaning long into the next NXXT drop 💥 trend strong, supply tight, insider alignment. One clean beat and tape does the rest 🚀
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 27 at 3:40 PM
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis $DYN $RNA $NVS https://stocktwits.com/news/equity/markets/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7
0 · Reply
wwmeinc
wwmeinc Oct. 27 at 3:17 PM
$RNA ....Have not seen a deal that was not completed by $NVS once they have set their sights on acquiring a biotech/drug and in our case a very interesting platform in which to expand and grow....odds really favour this deal...and the cardio/heart spinco is a really nice touch to this deal...I am not greedy though....might end up leaving some profits on the table but then the biotech sector has unlimited possibilites to re-invest and carry-on down this path/sector...just some thoughts. glta
0 · Reply
27R
27R Oct. 27 at 2:49 PM
$NVS Earnings release before tomorrow's open, significant post-earnings volatility with relatively reasonable implied volatility, perhaps consider a Straddle
0 · Reply
isaac_armstrong07
isaac_armstrong07 Oct. 27 at 2:06 PM
$NVS NXXT mixes 35M float record revs and Russell inclusion. Base near 1.80 created room. If growth cadence persists, the path to 6 becomes straightforward on a multiple reset
0 · Reply
hio133
hio133 Oct. 27 at 1:33 PM
$NVO so $NVS ??? LOL
0 · Reply
HyacinthCohen
HyacinthCohen Oct. 27 at 1:23 PM
$NVS roche and seretpa have a strong hold on the dmd market. Novartis just paid billions for pennies in market share
0 · Reply
Latest News on NVS
5 Things to Know Before the Stock Market Opens

Oct 27, 2025, 9:05 AM EDT - 5 hours ago

5 Things to Know Before the Stock Market Opens

RNA


Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 9 hours ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

RNA


Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

Oct 26, 2025, 5:33 PM EDT - 21 hours ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

RNA


Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 22 hours ago

Novartis to acquire Avidity Biosciences for about $12B

RNA


Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 23 hours ago

Novartis Deal Values Avidity Biosciences At $12 Billion

RNA


Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 1 day ago

Novartis to acquire Avidity Biosciences for $12 billion

RNA


Novartis: Assessing The Impact Of Entresto Generics

Oct 16, 2025, 1:23 PM EDT - 11 days ago

Novartis: Assessing The Impact Of Entresto Generics


US FDA approves Novartis' drug for skin disease

Sep 30, 2025, 4:22 PM EDT - 26 days ago

US FDA approves Novartis' drug for skin disease


Novartis, Monte Rosa strike $5.7 billion drug development deal

Sep 15, 2025, 7:15 AM EDT - 6 weeks ago

Novartis, Monte Rosa strike $5.7 billion drug development deal


Novartis: Pipeline Progress And Buyback Drive Upside

Sep 3, 2025, 4:16 AM EDT - 7 weeks ago

Novartis: Pipeline Progress And Buyback Drive Upside


keypatience
keypatience Oct. 27 at 5:16 PM
$XBI $NVS Novartis on a buying spree
0 · Reply
Stone52
Stone52 Oct. 27 at 4:20 PM
$AQST $SPRY $NVS $RNA M&A in the biotech space continues to heat up as Novartis is buying U.S. biotech firm Avidity Biosciences for about $12 billion in cash - announced this morning. Neither AQST or SPRY will be stand-alone companies at some point.
1 · Reply
Jaythelest
Jaythelest Oct. 27 at 4:10 PM
$NVS $DYN So logically $ONCY are the next to be acquire , they need us 💪
0 · Reply
DarkWave_12
DarkWave_12 Oct. 27 at 3:57 PM
$NVS I’m leaning long into the next NXXT drop 💥 trend strong, supply tight, insider alignment. One clean beat and tape does the rest 🚀
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 27 at 3:40 PM
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis $DYN $RNA $NVS https://stocktwits.com/news/equity/markets/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7
0 · Reply
wwmeinc
wwmeinc Oct. 27 at 3:17 PM
$RNA ....Have not seen a deal that was not completed by $NVS once they have set their sights on acquiring a biotech/drug and in our case a very interesting platform in which to expand and grow....odds really favour this deal...and the cardio/heart spinco is a really nice touch to this deal...I am not greedy though....might end up leaving some profits on the table but then the biotech sector has unlimited possibilites to re-invest and carry-on down this path/sector...just some thoughts. glta
0 · Reply
27R
27R Oct. 27 at 2:49 PM
$NVS Earnings release before tomorrow's open, significant post-earnings volatility with relatively reasonable implied volatility, perhaps consider a Straddle
0 · Reply
isaac_armstrong07
isaac_armstrong07 Oct. 27 at 2:06 PM
$NVS NXXT mixes 35M float record revs and Russell inclusion. Base near 1.80 created room. If growth cadence persists, the path to 6 becomes straightforward on a multiple reset
0 · Reply
hio133
hio133 Oct. 27 at 1:33 PM
$NVO so $NVS ??? LOL
0 · Reply
HyacinthCohen
HyacinthCohen Oct. 27 at 1:23 PM
$NVS roche and seretpa have a strong hold on the dmd market. Novartis just paid billions for pennies in market share
0 · Reply
joshua_harrington07
joshua_harrington07 Oct. 27 at 1:22 PM
$NVS NXXT plan for strength accumulate 2.02 to 2.04 print 2.05 early and momentum traders typically chase to 2.08 then 2.12 volume needs 150k by 9 45 ET for the trend day setup
0 · Reply
LaurenHayes887
LaurenHayes887 Oct. 27 at 1:14 PM
$NVS Novartis is making waves by acquiring $RNA Avidity Biosciences for $12B at $72/share, a remarkable 46% premium. This strategic move bolsters Novartis’ neuromuscular pipeline, harnessing Avidity’s cutting-edge RNA technology to advance gene therapies targeting muscles and unlock new possibilities for treating muscular dystrophy.
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 27 at 1:10 PM
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology $OTLC $IOBT $NVS $BCAX $PFE https://ibn.fm/3BZ5O
0 · Reply
topstockalerts
topstockalerts Oct. 27 at 12:39 PM
Pharmaceutical giant Novartis announced on Monday that it has reached an agreement to acquire U.S.-based Avidity Biosciences, a leader in RNA-based therapies, for $12 billion. Novartis highlighted that Avidity will bring a new class of RNA therapies for serious genetic neuromuscular diseases, and its advanced neuroscience programs will be integrated into Novartis. Other early-stage research from Avidity, primarily in cardiology, will be spun off into a new company, they explained. Novartis offered Avidity shareholders $72 in cash per share, representing a 46% premium over Friday's closing price, or 62% over the volume-weighted average price of the last 30 trading sessions. Both companies' boards have unanimously recommended that Avidity shareholders accept the offer. The deal is expected to close in the first half of 2026, subject to approval by relevant authorities and Avidity’s shareholders in California. $RNA $NVS
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 27 at 12:31 PM
$RNA (+43.3% pre) $NVS Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash ($72.00/sh) - CNBC https://ooc.bz/l/81920
0 · Reply
Tokenist
Tokenist Oct. 27 at 12:27 PM
💥 $RNA rockets +43% premarket! Biotech player Avidity Biosciences just got scooped up by $NVS (Novartis) in a $12B cash deal — $72/share 💰 🧬 The move gives Novartis access to Avidity’s RNA-targeting platform and three late-stage drugs for rare muscle diseases — DMD, DM1, and FSHD — each with billion-dollar potential. 🔥 Avidity investors are getting a 46% premium over Friday’s close ($49.15) and a 62% bump over its 30-day average. The deal also spins out a new “SpinCo” focusing on genetic cardiomyopathies, shareholders get 1 SpinCo share per 10 RNA shares held. 📈 $RNA now trades near $70.68, up 43% before the bell and it’s sending shockwaves through the RNA biotech space, with $DYN also jumping +20%. Biggest biotech M&A headline of the month — RNA just cashed out big time. 💸
2 · Reply
notreload_ai
notreload_ai Oct. 27 at 10:55 AM
$NVS acquires $RNA for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs. https://notreload.xyz/novartis-avidity-biosciences/
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Oct. 27 at 10:45 AM
$ETH.X $NVS $RNA $BA The price of Ethereum jumped about 6% on Sunday, performing better than most cryptocurrencies that day. https://www.earlybird.email/p/ethereum-nears-fusaka-upgrade
0 · Reply
Shanthi_Rexaline
Shanthi_Rexaline Oct. 27 at 10:08 AM
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today https://stocktwits.com/news-articles/markets/equity/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma $RNA $NVS $IBB $XBI
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 27 at 10:07 AM
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today $RNA $IWC $NVS $XBI https://stocktwits.com/news/equity/markets/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma
0 · Reply
ChessGM
ChessGM Oct. 27 at 2:12 AM
$NVS "Heads up alert! Only three days until Upcoming earnings on Tuesday, 10/28/2025 for $NVS Bullish (8.2) In recent evaluations, Novartis (NVS) has demonstrated a robust trajectory, characterized by positive developments across its drug pipeline and significant financial performance metrics. The company recently showcased promising results from its immunology advancements, particularly with drugs like ianalumab and Cosentyx, which are pivotal in treating complex autoimmune diseases. Financially, Novartis is positioned favorably with a Price-to-Earnings (P/E) ratio of approximately 15.5, which is lower than the industry average of around 18, indicating potential undervaluation. The company has reported an impressive Earnings Per Share (EPS) growth rate of 12% year-over-year, outpacing many of its peers in the pharmaceutical sector. Revenue forecasts remain optimistic, with projections estimating a compound annual growth rate (CAGR) of 5% over the next five years, driven by strong sales in emerging markets and innovative therapies. Comparatively, Novartis's performance stands out against industry peers like Pfizer and Roche, which face more significant headwinds due to patent expirations and regulatory challenges. Looking ahead, Novartis is gearing up for its upcoming earnings report, scheduled for October 28, 2025. Analysts anticipate a strong performance, with consensus estimates predicting revenues of approximately $13.5 billion and an EPS of $1.X.25, reflecting a solid year-over-year growth. The historical performance of Novartis during previous earnings seasons has been strong, often exceeding analyst expectations, which could positively influence investor sentiment and stock performance post-announcement. The potential impact of this earnings report is heightened by the recent approval of Rhapsido for chronic spontaneous urticaria, which could add significant revenue streams moving forward. In terms of sector performance, the pharmaceuticals and biotechnology sector has shown resilience amid broader market volatility, with many companies, including Novartis, benefiting from increased demand for innovative therapies and a favorable regulatory environment. The sector's overall growth is supported by advancements in gene therapies, biologics, and a growing focus on chronic disease management, positioning Novartis well within this expanding market landscape. - Funds were net sellers of $NVS during the previous reporting quarter. - Funds with large holdings in $NVS include: - Primecap Management, MV: $1.X,259MM. Fund Rank: 63% - Point72 Asset Management LP, MV: $90MM. Fund Rank: 91% www.point72.com - The Investment House LLC, MV: $10MM. Fund Rank: 89% www.tihllc.com - GQG Partners LLC, MV: $8MM. Fund Rank: 84% - Fayez Sarofim & Co, MV: $3MM. Fund Rank: 68% www.sarofim.com - Last 10 days performance: 0% - Last 30 days performance: 6% - Last 90 days performance: 11% Some of the latest news articles: - Title: Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases Publication Date: 10/25/2025 3:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/novartis-showcases-significant-immunology-advancements-150000476.html?.tsrc=rss - Title: Novartis (SWX:NOVN): Exploring Valuation Perspectives as Shares Gain 12% Over Three Months Publication Date: 10/25/2025 9:08:05 AM, Source: yahoo URL: https://finance.yahoo.com/news/novartis-swx-novn-exploring-valuation-090805326.html?.tsrc=rss - Title: Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week Publication Date: 10/24/2025 7:19:51 PM, Source: yahoo URL: https://finance.yahoo.com/m/77a11bbc-3994-38fc-84d5-d5ae7873d19c/fed-rate-move%2C-apple.html?.tsrc=rss - Title: Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key Publication Date: 10/24/2025 2:33:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/biogen-beat-q3-earnings-leqembi-143300083.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 26 at 11:10 PM
$RNA $NVS Got a acquisition here Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline "Pursuant to the terms of the merger agreement, holders of Avidity common stock will receive USD 72.00 per share in cash at closing, representing a premium of approximately 46% over Avidity's closing share price on October 24, 2025 of USD 49.15 and approximately 62% over Avidity's October 24 closing 30-day volume weighted average price of USD 44.42, and valuing the company at approximately USD 12.0 billion on a fully diluted basis. Avidity stockholders will also receive consideration for the separation of the SpinCo business."
0 · Reply